develop
safe
effect
vaccin
prevent
control
emerg
neglect
infecti
diseas
intern
prioriti
develop
similar
control
measur
bioterrorist
threat
intern
standard
establish
ensur
protect
human
subject
scientif
integr
clinic
trial
studi
design
data
collect
gener
overview
histori
regulatori
guidelin
ethic
principl
underpin
vaccin
develop
process
provid
emphasi
clinic
trial
conduct
unit
state
contemporari
vaccin
develop
process
involv
sequenti
assess
safeti
immunogen
efficaci
clinic
trial
process
alway
linear
straightforward
adapt
flexibl
clinic
trial
design
increas
likelihood
success
outcom
efficaci
vaccin
number
diseas
discuss
volum
test
directli
human
altern
approach
develop
address
challeng
major
element
typic
clinic
trial
protocol
discuss
checklist
essenti
document
support
trial
provid
novel
vaccin
approach
technolog
emerg
regulatori
ethic
consider
need
revisit
adapt
respond
everchang
landscap
vaccin
consid
among
valuabl
costeffect
tool
control
infecti
diseas
inde
univers
immun
infant
children
varieti
pathogen
consid
one
top
ten
achiev
centuri
cdc
major
scientif
technic
ethic
regulatori
principl
andor
process
underpin
vaccin
develop
evalu
process
defin
howev
challeng
pose
threat
bioterror
emerg
infecti
diseas
well
technolog
advanc
composit
formul
deliveri
vaccin
expos
gap
polici
practic
requir
ongo
consider
refin
approach
evalu
new
vaccin
purpos
chapter
provid
brief
overview
approach
evalu
candid
vaccin
human
particular
attent
issu
relat
vaccin
biodefens
emerg
neglect
diseas
major
focu
clinic
trial
protocol
develop
us
although
mani
principl
regul
practic
harmon
across
globe
brief
overview
relat
regulatori
issu
preclin
vaccin
develop
provid
howev
detail
discuss
topic
found
elsewher
volum
us
vaccin
regul
biolog
although
vaccin
legal
defin
drug
food
drug
cosmet
act
fdca
ethic
principl
regulatori
agenc
requir
guid
product
develop
clinic
research
centuri
evolv
progress
centuri
mani
case
develop
codifi
guidelin
establish
regulatori
author
spur
tragic
accid
clear
ethic
breech
review
histor
consider
see
baylor
midthun
borcher
et
al
number
children
becam
ill
die
treatment
diphtheria
antitoxin
contamin
tetanu
toxin
episod
result
first
legisl
design
regul
puriti
potenc
biolog
biolog
control
act
bca
peopl
die
ingest
elixir
sulfanilamid
contain
diethylen
glycol
antifreez
lead
enact
fdca
ballentin
provis
fdca
requir
manufactur
submit
safeti
data
food
drug
administr
fda
prior
registr
kefauv
harri
amend
fdca
requir
efficaci
data
also
submit
public
health
servic
act
incorpor
bca
section
us
code
feder
regul
cfr
gave
feder
govern
author
licens
biolog
manufactur
facil
incomplet
inactiv
polioviru
vaccin
result
develop
polio
number
children
cutter
incid
led
establish
divis
biolog
standard
db
within
nih
offit
author
vest
db
transfer
fda
organ
current
respons
regul
biolog
center
biolog
evalu
research
cber
fda
titl
cfr
contain
regul
pertain
biolog
includ
product
standard
manufactur
label
licens
advertis
investig
use
protect
human
subject
inform
consent
nonclin
laboratori
studi
institut
review
board
irb
part
titl
cfr
contain
regul
relat
investig
new
drug
applic
ind
cfr
updat
year
reflect
chang
polici
procedur
addit
guidanc
document
relat
vaccin
publish
fda
appropri
intern
group
compris
scientist
regul
ethicist
pharmaceut
repres
conven
discuss
standard
design
implement
document
report
clinic
trial
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
ich
establish
guidelin
conduct
clinic
research
good
clinic
practic
gcp
mani
adopt
us
fda
fda
ich
gcp
provid
unifi
standard
ensur
qualiti
clinic
trial
data
protect
human
subject
european
union
japan
us
clinic
trial
support
licensur
new
vaccin
drug
research
relat
evalu
vaccin
emerg
neglect
diseas
implement
gcp
develop
countri
may
pose
uniqu
challeng
acosta
et
al
conduct
multin
clinic
trial
vi
polysaccharid
typhoid
fever
vaccin
asia
among
individu
implement
gcp
requir
adapt
order
compli
goal
guidelin
revel
nazi
physician
tortur
experi
prison
world
war
ii
culmin
public
nuremberg
code
macra
code
recogn
first
set
ethic
guidelin
human
research
recogn
intern
commun
declar
helsinki
articul
addit
respons
investig
research
subject
pave
way
develop
irb
continu
violat
inform
consent
summar
new
england
journal
medicin
articl
written
dr
henri
beecher
articl
subsequ
expos
ethic
violat
perpetr
tuskeeg
syphili
studi
led
nation
research
act
establish
irb
nation
commiss
protect
human
subject
biomed
behavior
research
consid
principl
practic
human
research
us
commiss
publish
belmont
report
report
defin
three
major
ethic
principl
relat
clinic
trial
applic
pertain
human
research
respect
person
inform
consent
benefic
riskbenefit
assess
justic
equit
subject
select
recommend
nation
bioethic
commiss
relat
research
involv
human
subject
adopt
feder
law
socal
common
rule
cfr
subpart
articul
feder
polici
protect
human
subject
particip
clinic
trial
addit
protect
pregnant
women
fetus
prison
children
outlin
subpart
b
c
cfr
council
intern
organ
medic
scienc
form
recent
publish
updat
intern
ethic
guidelin
research
involv
human
subject
ciom
abundantli
clear
ethic
consider
regulatori
guidelin
conduct
clinic
research
inextric
intertwin
ethic
consider
drive
need
regul
conduct
clinic
trial
ensur
protect
human
subject
qualiti
integr
data
gener
seven
ethic
requir
fulfil
conduct
clinic
research
propos
emanuel
et
al
research
provid
inform
advanc
scienc
knowledg
valu
scientif
valid
fair
subject
select
favor
riskbenefit
ratio
independ
review
inform
consent
respect
enrol
subject
increas
complex
redund
oversight
contemporari
clinic
trial
reflect
commit
accomplish
goal
simplifi
prototyp
organiz
structur
vaccin
research
clinic
trial
shown
fig
detail
regard
role
respons
particip
clinic
trial
process
provid
major
stage
vaccin
develop
outlin
fig
initi
stage
refer
preind
investig
new
drug
stage
activ
conduct
stage
culmin
product
vaccin
evalu
human
ind
stage
vaccin
shown
safe
pure
effect
human
may
licens
use
licens
postmarket
stage
public
health
need
control
diseas
mean
vaccin
identifi
detail
studi
design
understand
pathogenesi
infect
identifi
immun
respons
associ
protect
conduct
studi
may
involv
assess
infect
immun
human
diseas
occur
natur
frequenc
high
enough
permit
evalu
interpandem
influenza
malaria
tuberculosi
other
howev
detail
evalu
rare
lethal
diseas
particularli
includ
center
diseas
control
prevent
cdc
categori
biothreat
list
must
studi
anim
model
might
predict
patholog
immun
respons
occur
human
smallpox
tularemia
inhal
anthrax
hemorrhag
fever
virus
etc
candid
vaccin
formul
contain
express
epitop
elicit
immun
respons
associ
protect
design
evalu
vitro
anim
safeti
immunogen
profil
establish
critic
part
preind
stage
develop
valid
manufactur
process
candid
vaccin
typic
undergo
sequenti
seri
evalu
human
three
major
phase
identifi
summar
tabl
practic
scheme
straightforward
phase
phase
clinic
trial
may
overlap
combin
multipl
phase
andor
phase
evalu
may
necessari
adjust
dosag
chang
regimen
evalu
age
andor
risk
group
even
pivot
phase
studi
demonstr
efficaci
close
ongo
commun
sponsor
regulatori
agenc
investig
irb
critic
throughout
ind
stage
includ
preind
meet
endofphas
meet
prebiolog
licens
applic
bla
bla
meet
facilit
time
progress
clinic
trial
process
first
evalu
candid
vaccin
human
refer
phase
clinic
trial
typic
less
healthi
young
adult
subject
enrol
phase
trial
fact
number
may
consider
smaller
novel
product
case
investig
may
elect
inocul
hand
subject
exclud
possibl
unexpect
reactogen
toxic
keitel
et
al
major
goal
phase
trial
assess
safeti
toler
howev
preliminari
immunogen
assess
doserang
inform
provid
valuabl
inform
regard
dosag
select
subsequ
evalu
although
design
phase
clinic
trial
drug
often
openlabel
mani
contemporari
phase
clinic
trial
candid
vaccin
random
doubleblind
placebocontrol
trial
phase
trial
may
perform
stage
small
cohort
subject
vaccin
observ
period
week
remaind
studi
cohort
vaccin
stage
approach
reduc
exposur
subject
occurr
unexpect
toxic
vaccin
produc
us
whose
ultim
use
countri
malaria
vaccin
initi
evalu
occur
us
phase
follow
phase
test
healthi
popul
target
countri
inclus
placebo
phase
develop
reduc
bia
assess
advers
event
ae
seriou
ae
sae
provid
intern
control
laboratori
assess
immun
respons
follow
immun
number
subject
enrol
phase
trial
small
studi
lack
statist
power
detect
ae
occur
low
rate
nevertheless
small
care
monitor
phase
trial
identifi
unexpect
andor
unaccept
toxic
requir
reformul
reevalu
potenti
candid
keitel
et
al
edelman
et
al
circumst
specif
monitor
subject
phase
phase
trial
evid
infect
immun
relev
particularli
concern
vaccin
might
elicit
immunopatholog
respons
vaccin
subject
natur
infect
immunopatholgi
result
sever
atyp
infect
andor
death
occur
among
person
immun
inactiv
measl
vaccin
infant
given
inactiv
vaccin
prevent
respiratori
syncyti
viru
rsv
vaccin
polack
similar
concern
exist
regard
potenti
dengu
viru
sar
coronaviru
vaccin
elicit
immunopatholog
respons
edelman
et
al
deme
et
al
although
specif
relev
chapter
exploratori
ind
studi
may
preced
typic
concomit
administr
vaccin
biolog
medic
exampl
administr
new
vaccin
infant
context
increasingli
complic
childhood
immun
schedul
pose
complex
problem
evid
simultan
administr
licens
experiment
vaccin
interfer
protect
respons
compon
either
product
necessari
rennel
et
al
vaccin
candid
shown
safe
possess
accept
reactogen
immunogen
profil
assess
efficaci
undertaken
phase
clinic
trial
type
size
popul
studi
depend
epidemiolog
target
diseas
popul
risk
diseas
diseas
attack
rate
level
protect
confer
via
immun
phase
clinic
trial
prevent
diseas
occur
low
incid
may
requir
hundr
thousand
subject
us
field
trial
inactiv
polioviru
vaccin
franci
wherea
phase
trial
vaccin
prevent
highincid
infect
rsv
infant
theoret
would
requir
hundr
subject
particularli
vaccin
expect
highli
efficaci
assess
efficaci
vaccin
agent
bioterror
well
vaccin
candid
pandem
influenza
may
problemat
exampl
smallpox
inhal
anthrax
hemorrhag
fever
virus
tularemia
plagu
influenza
occur
natur
frequenc
high
enough
permit
control
evalu
clinic
vaccin
efficaci
prior
licensur
vaccin
fda
final
rule
entitl
new
drug
biolog
drug
product
evid
need
demonstr
effect
new
drug
human
efficaci
studi
ethic
feasibl
otherwis
refer
anim
rule
publish
address
circumst
fda
rule
permit
use
anim
efficaci
data
collect
human
efficaci
data
feasibl
safeti
immunogen
data
human
anim
efficaci
data
use
support
licensur
sever
condit
met
follow
pathophysiolog
infect
reason
well
understood
pathogenesi
immun
respons
one
two
anim
speci
expect
predict
respons
human
immunogen
endpoint
correl
protect
anim
relat
human
immun
respons
immunogen
phase
evalu
assess
drug
therapeut
biolog
fda
exploratori
ind
studi
option
character
small
earli
phase
trial
therapeut
diagnost
intent
rather
goal
assess
feasibl
develop
drug
biolog
goal
type
studi
may
includ
determin
mechan
action
drug
human
evalu
pharmacokinet
profil
agent
select
one
group
promis
candid
explor
biodistribut
characterist
use
imag
techniqu
studi
pose
lower
potenti
risk
subject
exploratori
ind
studi
requir
less
differ
preclin
support
typic
phase
studi
vaccin
candid
favor
safeti
immunogen
profil
phase
trial
may
progress
expand
phase
trial
sever
hundr
healthi
subject
may
enrol
phase
trial
major
goal
phase
trial
assess
safeti
develop
optim
regimen
immun
typic
sever
dosag
level
evalu
differ
immun
regimen
number
dose
interv
dose
also
may
explor
phase
trial
random
doubleblind
placebocontrol
trial
although
larger
number
subject
evalu
phase
trial
still
lack
statist
power
detect
event
occur
low
proport
subject
initi
phase
trial
usual
conduct
among
person
low
risk
acquir
target
diseas
therefor
addit
phase
phase
trial
may
necessari
assess
safeti
immunogen
among
popul
high
risk
diseas
pivot
efficaci
trial
conduct
sever
emerg
neglect
diseas
preliminari
efficaci
vaccin
assess
human
challeng
model
includ
malaria
influenza
cholera
couch
et
al
epstein
et
al
tacket
et
al
care
control
experiment
inocul
subject
target
pathogen
provid
proof
concept
immun
vaccin
candid
confer
protect
prior
larg
phase
clinic
trial
pediatr
popul
rechalleng
vaccin
subject
homolog
relat
live
attenu
influenza
viru
vaccin
laiv
provid
support
evid
intranas
immun
laiv
would
confer
protect
subsequ
infect
wildtyp
influenza
virus
belsh
et
al
phase
trial
may
also
incorpor
plan
assess
endpoint
anim
human
suffici
well
understood
permit
select
regimen
would
expect
predict
protect
human
diseas
correl
protect
reason
well
defin
exampl
serum
hai
antibodi
level
influenza
virus
surrog
marker
use
support
licensur
fda
final
order
facilit
approv
vaccin
sever
lifethreaten
ill
addit
mechan
expedit
review
acceler
approv
develop
fda
regulatori
author
increasingli
requir
addit
studi
conduct
market
approv
phase
studi
may
also
initi
sponsor
varieti
reason
vaccin
appear
safe
studi
thousand
individu
rare
advers
event
may
observ
hundr
thousand
even
million
peopl
vaccin
occur
firstgener
live
attenu
rotaviru
vaccin
murphi
et
al
longterm
safeti
continu
efficaci
vaccin
may
unknown
time
licensur
benefit
immun
special
popul
may
underrepres
studi
ind
stage
may
interest
unfortun
phase
clinic
trial
typic
random
may
uncontrol
nevertheless
sever
safeti
surveil
system
establish
facilit
earli
detect
potenti
rare
seriou
reaction
vaccin
includ
vaccin
advers
event
report
system
vaer
vaccin
safeti
datalink
vsd
american
academi
pediatr
practic
research
offic
set
pro
ellenberg
et
al
design
option
phase
studi
includ
casecontrol
studi
cohort
studi
design
protocol
evalu
candid
vaccin
requir
consider
pathogen
diseas
pathogenesi
immun
respons
profil
characterist
vaccin
candid
success
clinic
trial
depend
implement
welldesign
protocol
follow
care
monitor
retent
subject
close
adher
protocol
accur
report
document
observ
made
trial
comprehens
discuss
see
chow
liu
meinert
wang
bakhai
brief
outlin
essenti
element
inclus
clinic
trial
protocol
shown
tabl
detail
templat
protocol
develop
prepar
nation
institut
allergi
infecti
diseas
use
guid
protocol
develop
niaid
novel
construct
live
attenu
vaccin
may
requir
addit
discuss
risk
special
facil
isol
evalu
live
attenu
vaccin
base
potenti
pandem
influenza
virus
note
basic
protocol
element
mirror
inform
consent
document
background
rational
provid
inform
regard
current
understand
diseas
epidemiolog
pathogenesi
immun
respons
relev
protect
infect
need
develop
control
measur
sourc
adapt
niaid
protocol
templat
guidanc
niaid
clinic
trial
protocol
develop
serv
control
vaccin
black
et
al
case
meningococc
control
vaccin
provid
potenti
benefit
studi
particip
flexibl
adapt
design
method
frequent
employ
develop
vaccin
incorpor
plan
modif
clinic
trial
design
made
conduct
research
chow
chang
adapt
ongo
trial
may
includ
prospect
adapt
interim
analysi
stop
rule
earli
termin
due
futilitysafeti
concernsefficaci
sampl
size
reestim
ad
hoc
adapt
chang
inclus
exclus
criteria
dosag
regimen
alter
trial
durat
retrospect
adapt
end
studi
unblind
includ
chang
studi
endpoint
alter
statist
hypothesi
superior
noninferior
goal
approach
permit
modif
base
accumul
evid
alter
trial
design
increas
probabl
success
without
undermin
valid
trial
gallo
et
al
adapt
may
requir
modif
studi
hypothes
protocol
amend
sampl
size
recalcul
clinic
trial
also
classifi
singlecent
multicent
studi
phase
studi
often
singlecent
studi
howev
multicent
trial
design
may
use
phase
clinic
vaccin
develop
multicent
studi
design
provid
sever
advantag
enrol
subject
expedit
result
trial
like
generaliz
studi
endpoint
need
clearli
identifi
phase
trial
safeti
toler
reactogen
primari
endpoint
may
includ
frequenc
sever
inject
site
reaction
pain
tender
red
swell
system
reaction
fever
chill
headach
myalgia
arthralgia
etc
well
laboratori
evid
advers
reaction
hematolog
biochem
phase
clinic
trial
specif
immun
respons
defin
time
point
immun
typic
character
primari
endpoint
safeti
reactogen
may
primari
secondari
endpoint
phase
clinic
trial
protect
laboratoryconfirm
infect
andor
diseas
primari
endpoint
major
safeti
assess
may
frequenc
sae
associ
administr
investig
agent
detail
descript
propos
studi
popul
number
subject
studi
must
provid
specif
characterist
age
rang
scientif
rational
select
vaccin
candid
discuss
concis
descript
studi
agent
provid
includ
summari
preclin
studi
relev
clinic
studi
final
potenti
risk
benefit
immun
investig
agent
delin
object
purpos
trial
clearli
explicitli
state
phase
trial
primari
object
assess
safeti
toler
reactogen
vaccin
wherea
assess
immunogen
secondari
object
combin
phase
phase
clinic
trial
safeti
immunogen
may
coprimari
endpoint
exploratori
endpoint
may
also
includ
effect
age
race
gender
immun
respons
combin
phase
trial
may
propos
vaccin
candid
repres
variant
previous
licens
construct
subvirion
influenza
vaccin
prevent
avian
influenza
treanor
et
al
efficaci
safeti
typic
primari
endpoint
phase
trial
studi
design
describ
clinic
trial
candid
vaccin
studi
design
typic
random
doubleblind
control
clinic
trial
one
exampl
parallel
group
design
phase
safeti
toler
studi
often
util
titrat
design
ascend
dosag
experiment
agent
sequenti
administ
new
cohort
subject
gors
et
al
clusterrandom
clinic
trial
design
occasion
employ
assess
vaccin
efficaci
circumst
larger
group
individu
nurs
home
school
random
intervent
rather
individu
subject
clinic
endpoint
ascertain
vaccin
subject
rodrigu
et
al
subset
cluster
contact
healthcar
worker
close
set
hayward
et
al
phase
clinic
trial
histor
openlabel
howev
recent
year
phase
clinic
trial
vaccin
random
blind
valu
placebo
control
clinic
trial
describ
howev
licens
control
vaccin
may
use
rather
placebo
particularli
phase
clinic
trial
children
recent
phase
clinic
trial
pneumococc
conjug
vaccin
infant
meningococc
type
c
vaccin
health
statu
abil
provid
inform
consent
etc
potenti
elig
person
inclus
criteria
factor
would
render
individu
inelig
exclus
criteria
explicitli
enumer
phase
trial
screen
elig
may
includ
medic
histori
physic
examin
laboratori
screen
evid
good
health
normal
hematolog
biochem
paramet
evid
activ
hepat
b
hepat
c
hiv
infect
inform
regard
serosuscept
candid
pathogen
may
necessari
exampl
phase
clinic
trial
dengu
viru
vaccin
may
requir
evid
prior
infect
caus
virus
edelman
et
al
phase
clinic
trial
assess
immunogen
laiv
may
focu
person
low
absent
level
preexist
immun
candid
vaccin
keitel
et
al
phase
clinic
trial
necessari
identifi
popul
infect
diseas
occur
high
enough
frequenc
assess
abil
vaccin
protect
exampl
pivot
phase
trial
inactiv
hepat
vaccin
conduct
specif
us
commun
rate
hepat
infect
children
high
werzberg
et
al
human
subject
consider
may
includ
descript
certain
behavior
andor
concomit
medic
would
exclud
subject
clinic
trial
vaccin
women
capabl
bear
children
must
consent
certain
birth
control
measur
us
depart
health
human
servic
dhh
publish
guidanc
regard
research
pregnant
women
research
conduct
popul
must
direct
benefit
woman
fetu
must
minim
risk
fetu
inform
obtain
way
mani
phase
clinic
trial
use
prescript
medic
permit
clinic
trial
vaccin
potenti
could
transmit
other
commun
rais
special
concern
recent
reevalu
smallpox
vaccin
pose
concern
regard
transmiss
vaccin
viru
subject
contact
frey
et
al
case
person
household
signific
contact
young
infant
peopl
eczema
pregnant
women
immunocompromis
individu
exclud
particip
method
test
articl
alloc
also
describ
phase
phase
clinic
trial
vaccin
subject
random
receiv
one
sever
dosag
level
vaccin
placebo
ideal
random
occur
subject
qualifi
particip
typic
random
occur
block
prespecifi
number
repres
multipl
number
test
articl
exampl
four
dosag
level
vaccin
placebo
block
size
might
block
size
chosen
subject
would
random
block
random
reduc
risk
unequ
group
size
circumst
probabl
receiv
one
product
differ
probabl
receiv
anoth
exampl
efficaci
studi
conduct
children
investig
may
wish
reduc
number
subject
random
receiv
placebo
random
scheme
select
may
vaccin
placebo
vaccin
group
assign
subject
conceal
subject
investig
reduc
bia
assess
perform
vaccin
socal
doubl
blind
addit
measur
taken
reduc
potenti
imbal
baselin
characterist
enrol
subject
stratif
subject
accord
age
prior
receipt
relat
vaccin
etc
prior
random
clinic
trial
protocol
contain
basic
inform
regard
character
vaccin
formul
includ
dosag
packag
label
storag
prepar
administr
dose
account
method
studi
product
includ
placebo
andor
control
prepar
complet
descript
studi
vaccin
includ
manufactur
inform
preclin
clinic
safeti
immunogen
efficaci
provid
separ
investig
brochur
ib
inform
regard
use
concomit
medic
includ
prohibit
medic
detail
exampl
phase
clinic
trial
concomit
use
prescript
medic
may
prohibit
phase
clinic
trial
concomit
use
certain
medic
may
allow
antihypertens
medic
antidepress
gener
concomit
use
immunosuppress
immunomodulatori
cytotox
drug
would
prohibit
clinic
trial
live
attenu
vaccin
descript
propos
clinic
evalu
follow
phase
clinic
trial
detail
frequent
physic
assess
inject
site
system
respons
may
indic
well
review
subject
record
clinic
respons
follow
formul
fda
ae
defin
untoward
medic
event
occur
subject
receiv
studi
agent
sae
includ
death
lifethreaten
event
hospit
prolong
hospit
congenit
anomali
event
result
perman
disabl
ae
sae
record
assess
sever
relationship
vaccin
grade
ae
usual
base
interfer
activ
mild
interfer
usual
activ
moder
interfer
somewhat
usual
activ
sever
incapacit
sever
grade
system
laboratori
abnorm
establish
initi
trial
fda
suggest
guidelin
toxic
grade
scale
healthi
adult
adolesc
enrol
vaccin
clinic
trial
fda
contemporari
standard
assess
relationship
ae
immun
narrow
choic
associ
associ
ae
tempor
relat
administr
investig
agent
altern
etiolog
explain
event
consid
associ
sae
report
promptli
sponsor
turn
sponsor
must
notifi
fda
time
fashion
prospect
guidelin
discontinu
individu
vaccin
well
halt
rule
clinic
trial
outlin
typic
circumst
discontinu
individu
includ
sever
andor
hypersensit
reaction
follow
immun
develop
exclus
criterion
trial
failur
inabl
subject
compli
studi
procedur
note
everi
attempt
made
continu
follow
subject
safeti
assess
rule
halt
phase
clinic
trial
may
includ
occurr
one
two
hypersensit
reaction
sae
associ
investig
agent
occurr
moder
sever
reactogen
among
predefin
proport
subject
final
safeti
oversight
plan
describ
singlecent
trial
small
clinic
trial
safeti
monitor
committe
smc
consist
independ
safeti
monitor
ism
site
independ
member
expert
relev
protocol
respons
review
trial
result
period
ad
hoc
basi
make
recommend
sponsor
regard
conduct
clinic
trial
larger
multicent
trial
data
safeti
monitor
board
dsmb
consist
site
ism
individu
clinic
statist
expert
relev
protocol
constitut
review
studi
progress
advis
immun
intens
studi
assess
vari
accord
natur
studi
product
frequent
detail
assess
would
indic
novel
product
whose
safeti
profil
undefin
period
collect
blood
nasal
fecal
sampl
assess
occurr
toxic
determin
frequenc
magnitud
andor
durat
shed
live
vaccin
candid
may
also
indic
piedra
et
al
taylor
et
al
laboratori
assess
tailor
particular
need
protocol
base
pathogenesi
diseas
vaccin
evalu
inform
collect
preind
stage
brief
descript
type
specimen
collect
method
specimen
collect
prepar
handl
store
ship
applic
outlin
detail
procedur
provid
separ
manual
procedur
mop
studi
phase
trial
clinic
followup
specif
target
ascertain
whether
vaccin
prevent
infect
diseas
captur
occurr
sae
howev
limit
prospect
safeti
assess
may
includ
perhap
subset
subject
expand
safeti
databas
oxman
et
al
specif
clinic
laboratori
procedur
assess
safeti
immunogen
andor
efficaci
describ
detail
studi
schedul
indic
time
variou
assessmentsprocedur
intervent
outlin
includ
conduct
screen
enrol
followup
visit
clinic
assess
laboratori
procedur
complet
event
subject
particip
trial
termin
earli
describ
women
becom
pregnant
studi
final
descript
clinic
laboratori
assess
perform
event
subject
return
unschedul
visit
exampl
sever
vaccin
reaction
may
appropri
summari
tabl
figur
outlin
studi
procedur
particularli
use
describ
clinic
trial
protocol
detail
specif
safeti
paramet
monitor
cours
trial
along
method
time
assess
report
standard
definit
ae
sae
sponsor
smc
dsmb
may
recommend
termin
trial
unexpect
sever
toxic
continu
trial
review
ae
trigger
halt
rule
alter
sampl
size
base
interim
analys
protocol
modif
deem
necessari
complet
trial
success
clear
plan
monitor
conduct
clinic
trial
site
outlin
studi
protocol
specif
object
sitemonitor
visit
review
studi
document
ensur
protect
human
subject
complianc
gcp
clinic
laboratori
procedur
test
articl
administr
account
guidelin
accur
complet
data
collect
document
sponsor
may
conduct
monitor
visit
may
also
design
independ
contract
research
organ
cro
conduct
monitor
visit
regular
basi
throughout
trial
earli
monitor
visit
particularli
valuabl
order
identifi
systemat
unintent
deviat
protocol
detail
statist
analysi
plan
sap
prepar
restat
studi
hypothes
object
endpoint
describ
statist
basi
sampl
size
select
outlin
method
use
analyz
safeti
efficaci
interim
analys
plan
statist
issu
relat
discuss
clinic
trial
site
respons
protocol
complianc
accur
complet
data
collect
record
separ
document
sitespecif
standard
oper
procedur
sop
outlin
method
use
ensur
activ
accomplish
well
method
ensur
appropri
train
studi
staff
overal
qualiti
manag
plan
describ
protocol
descript
ethic
standard
follow
ensur
protect
human
subject
describ
us
complianc
cfr
part
ich
gcp
expect
protocol
indic
research
includ
screen
begin
protocol
consent
form
irbapprov
consent
process
describ
provis
subject
confidenti
health
insur
portabl
account
act
hipaa
enact
improv
portabl
continu
health
insur
coverag
nevertheless
contain
regul
direct
relev
clinic
research
dhh
exampl
inform
consent
document
requir
includ
extens
inform
particip
protect
health
inform
phi
kept
privat
administr
physic
technic
safeguard
must
adopt
ensur
secur
electron
phi
final
special
issu
relat
exclus
special
popul
women
minor
children
address
goal
data
manag
ensur
accuraci
complet
timeli
clinic
trial
data
collect
primari
respons
data
collect
rest
clinic
trial
site
addit
oversight
data
manag
respons
qualiti
review
analysi
report
may
share
sponsor
data
coordin
center
dcc
organiz
structur
data
manag
describ
part
protocol
data
captur
method
intern
qualiti
check
type
data
time
report
studi
record
retent
identif
protocol
deviat
correct
action
address
well
greater
detail
mop
addit
major
protocol
element
describ
full
protocol
includ
titl
page
statement
complianc
gcp
regulatori
guidelin
signatur
page
tabl
content
list
abbrevi
protocol
summari
list
key
personnel
role
descript
uniqu
facil
applic
list
refer
public
polici
appropri
appendic
list
essenti
document
file
trial
start
shown
tabl
addit
document
ad
trial
document
new
inform
becom
avail
protocol
amend
updat
irb
approv
train
certif
cv
screen
enrol
log
test
articl
account
shipment
log
monitor
report
consent
form
sourc
document
crf
commun
sponsor
etc
success
clinic
trial
hing
develop
care
design
protocol
although
discuss
clinic
trial
implement
beyond
scope
chapter
clear
protect
human
subject
scientif
integr
trial
design
document
overarch
goal
clinic
research
protocol
clinic
trial
protocol
must
document
process
use
ensur
goal
attain
conscienti
supervis
clinic
trial
activ
share
respons
investig
irb
sponsor
cro
dcc
safeti
oversight
committe
partner
particip
trial
meticul
attent
detail
strict
protocol
complianc
essenti
entir
studi
team
must
flexibl
prepar
respond
time
fashion
unexpect
find
novel
approach
develop
vaccin
biodefens
emerg
neglect
diseas
continu
evolv
requir
ongo
reconsider
ethic
regulatori
principl
practic
guid
conduct
clinic
trial
fda
courtesi
us
fda
